medEctoin® in Cough & Cold
Restoring all vitality: Allow people to manage their cold symptoms and support the self-healing powers of their bodies as effective as pharmacological compounds - without common side effects.
Scientific Proven Claims
Supporting Respiratory Health
Managing all common cold symptoms: medEctoin® alleviates symptoms of rhinitis as effective as pharmacological agents - but without the common side effects. Clinical studies have proven the following claims in pharyngitis, laryngitis and bronchitis.
-
Reduction of the Danger of Bacterial or Viral Infection in the Mouth and Throat.
medEctoin® forms a protective barrier in the respiratory tract, shielding it from environmental irritants that can aggravate cough and cold symptoms.
*based on pre-clinical data*
-
Effective Decongestion of the Nose and Sinuses.
The ability of medEctoin® to hydrate and protect the nasal mucosa combined with the natural decongestion effect of sea salt reduces blocked nose, runny nose, facial pain, headache and loss in smell and taste.
-
Reduction of Dry Cough.
By calming inflammation and irritation in the airways, medEctoin® can help decrease the frequency and severity of dry coughs.
-
Alleviation of Pain and Inflammation in the Throat.
The inflammation-reducing properties of medEctoin® reduce symptoms of acute Pharyngitis like hoarseness, sore throat, or pain on swallowing.
-
Promotion of the Self-Healing Process.
medEctoin® aids in the repair of irritated respiratory tissues by stabilizing cell membranes and enhancing the natural healing processes, helping the body recover from cold symptoms.
Clinically Proven:
medEctoin® in Cough & Cold
medEctoin® has clinically proven effect in all common cold illnesses. See these study results on how it manages symptoms in rhinitis, pharyngitis, laryngitis and bronchitis and provide the rest cycles the body needs to fight the infection.
As Effective as Xylometazoline
Participants
168 patients, aged ≥ 6 years diagnosed with acute rhinosinusitis.
Duration
7± 2 days
Method
Physicians assessed rhinosinusitis symptoms. Following treatment, investigators and patients judged the efficacy and tolerability.
Treatment
Products were applied within their defined intended use and in accordance with their respective instructions for use.
Ask an Expert
Prof. Dr. Ralph Mösges was the chairman of the International Standardization Committee for the Objective Assessment of the Upper Airways (ISCOANA), a task force of the International Rhinologic Society (IRS) and serves as a member of the guidelines committee of the German Academy of Otorhinolaryngology.
Success Stories
“We were the first to introduce a medEctoin® containing product. The medEctoin® really branded our company”.
Innomed
Management
Join the success story of medEctoin®: License our products under your brand
Your logo could soon be featured on these products – and all in just 8 months. Learn more about claims and applications by clicking on the product of your choice.
